News
GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China
GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug
Notice Regarding Business Alliance Between Sanbio and Ocumension in the Research, Development and Commercialization of Innovative Stem Cell Therapies for Ophthalmic Diseases
SanBio Co., Ltd. (Keita Mori, Representative Director and President, hereinafter “SanBio”) (TOKYO:4592) hereby announces that SanBio has entered into a business alliance with Ocumension (Hong Kong)
Edison Investment Research Limited: Edison issues outlook on SymBio Pharmaceuticals (4582)
Edison Investment Research Limited: Edison issues outlook on SymBio Pharmaceuticals (4582)
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan, SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore) (TOKYO: 4592), today announced that SB623 met the primary